BerGenBio
ISIN: NO0010650013 | Ticker: BGBIO | LEI: 213800TYYFXKYF3V2A23
Country: Norway
BerGenBio is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including cancer and severe respiratory infections.
AXL: a promising target to treat life-threatening diseases
The tyrosine kinase target AXL is known to play an important role in both the innate and adaptive immune systems, BerGenBio is developing two highly selective AXL inhibitors bemcentinib and tilvestamab.
Business model: R&D excellence and strategic partnerships
BerGenBio is leveraging its solid leadership position in understanding the role of AXL and related kinase signalling in diseases of high unmet need to develop a diversified pipeline of selective AXL inhibitors.
2007
Served areaWorldwide
HeadquartersMøllendalsbakken 9, 5867 Bergen – Norway
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 738,200,000.00 | 450,236,000.00 | 166,706,000.00 |
| Noncurrent Assets | N/A | 2,332,000.00 | 1,191,000.00 | 43,000.00 |
| Current Assets | N/A | 735,869,000.00 | 449,045,000.00 | 166,663,000.00 |
| Cash and cash equivalents | 253,586,000.00 | 721,641,000.00 | 436,646,000.00 | 150,803,000.00 |
| Other Current Assets | N/A | 14,228,000.00 | 12,398,000.00 | 15,860,000.00 |
| Equity And Liabilities | N/A | 738,200,000.00 | 450,236,000.00 | 166,706,000.00 |
| Equity | 219,754,000.00 | 670,229,000.00 | 384,426,000.00 | 88,498,000.00 |
| Issued Capital | N/A | 8,726,000.00 | 8,846,000.00 | 8,866,000.00 |
| Share Premium | N/A | 628,231,000.00 | 335,195,000.00 | 35,780,000.00 |
| Additional Paidin Capital | N/A | 33,272,000.00 | 40,386,000.00 | 43,852,000.00 |
| Liabilities | N/A | 67,971,000.00 | 65,810,000.00 | 78,208,000.00 |
| Noncurrent Liabilities | N/A | 1,367,000.00 | 942,000.00 | 275,000.00 |
| Longterm Borrowings | N/A | 1,367,000.00 | 942,000.00 | N/A |
| Current Liabilities | N/A | 66,604,000.00 | 64,868,000.00 | 77,933,000.00 |
| Current Provisions | N/A | 6,008,000.00 | 969,000.00 | 0.00 |
| Trade And Other Current Payables To Trade Suppliers | N/A | 22,550,000.00 | 26,726,000.00 | 29,634,000.00 |
| Other Current Liabilities | N/A | 38,046,000.00 | 37,172,000.00 | 48,299,000.00 |
| Line item in (nok) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue | 601,000.00 | 774,000.00 | 389,000.00 |
| Wages And Salaries | 48,832,000.00 | 69,929,000.00 | 66,143,000.00 |
| Other Employee Expense | 11,346,000.00 | 4,116,000.00 | 2,546,000.00 |
| Depreciation Expense | 726,000.00 | 1,312,000.00 | 883,000.00 |
| Other Expense By Nature | 200,788,000.00 | 239,880,000.00 | 236,451,000.00 |
| Profit Loss From Operating Activities | -261,091,000.00 | -314,464,000.00 | -305,635,000.00 |
| Finance Income | 19,499,000.00 | 15,993,000.00 | 15,027,000.00 |
| Finance Costs | 15,437,000.00 | 10,894,000.00 | 11,514,000.00 |
| Profit Loss Before Tax | -257,029,000.00 | -309,364,000.00 | -302,122,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -257,029,000.00 | -309,364,000.00 | -302,122,000.00 |
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Profit (loss) | N/A | -257,029,000.00 | -309,364,000.00 | -302,122,000.00 |
| Adjustments For Provisions | N/A | 3,934,000.00 | -5,039,000.00 | -969,000.00 |
| Adjustments For Unrealised Foreign Exchange Losses Gains | N/A | 710,000.00 | 667,000.00 | 3,280,000.00 |
| Adjustments For Sharebased Payments | N/A | 7,412,000.00 | 7,113,000.00 | 3,466,000.00 |
| Cash Flows From Used In Operating Activities | N/A | -234,290,000.00 | -303,340,000.00 | -288,231,000.00 |
| Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities | N/A | N/A | N/A | 299,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 67,000.00 | N/A | N/A |
| Interest Received Classified As Investing Activities | N/A | 3,614,000.00 | 3,130,000.00 | 2,949,000.00 |
| Cash Flows From Used In Investing Activities | N/A | 3,548,000.00 | 3,130,000.00 | 3,248,000.00 |
| Proceeds From Issuing Shares | N/A | 740,852,000.00 | 16,629,000.00 | 3,218,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 585,000.00 | 565,000.00 | 307,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 699,507,000.00 | 15,995,000.00 | 2,904,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | N/A | 468,765,000.00 | -284,216,000.00 | -282,080,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | N/A | -710,000.00 | -779,000.00 | -3,764,000.00 |
| Cash and cash equivalents | 253,586,000.00 | 721,641,000.00 | 436,646,000.00 | 150,803,000.00 |
Please note that some sums might not add up.
NO0010650013
LEI213800TYYFXKYF3V2A23
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.